| CASE REPORT |
|
| Year : 2022 | Volume
: 34
| Issue : 3 | Page : 373-378 |
|
|
Unilateral acute central serous chorioretinopathy with inactivated coronavirus disease 2019 vaccination: A case report and review of literature
Mojtaba Abrishami1, Seyedeh Maryam Hosseini2, Nasser Shoeibi2, Hamid Reza Heidarzadeh2
1 Eye Research Center, Mashhad University of Medical Sciences, Mashhad, Iran; Ocular Oncology Service, Department of Ophthalmology and Visual Sciences, University of Toronto, Toronto, Canada, Iran
2 Eye Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
Correspondence Address:
Hamid Reza Heidarzadeh
Eye Research Center, Khatam-Al-Anbia Eye Hospital, Qarani Blvd, Mashhad
Iran
 Source of Support: None, Conflict of Interest: None
DOI: 10.4103/joco.joco_41_22
|
|
|
Purpose: To report unilateral acute-onset central serous chorioretinopathy (CSC) following vaccination with inactivated coronavirus disease 2019 (COVID-19) vaccine in a healthy patient.
Methods: Case report and review of literature.
Results: A 39-year-old male was referred with sudden-onset, painless, unilateral blurred vision in the right eye. His first dose of the Sinopharm vaccine was injected 2 days before. A complete ocular examination revealed central subretinal fluid (SRF) accumulation in favor of CSC in the right eye. Systemic workup disclosed no previous COVID-19 infection or any systemic involvement. After 3 weeks, SRF decreased remarkably without treatment.
Conclusions: It is proposed that CSC development can be an ocular adverse effect of COVID-19 vaccination, although it is infrequent. Ophthalmologists should be aware of the possible association between COVID-19 vaccination and ocular adverse effects, but vaccination is the best effectual measure against COVID-19.
|
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
